ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aflibercept

Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.

Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.

Drug pageAflibercept: every studyMany companies study it; this page follows only the 86 they lead. All 268 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 2, 201286 company-led studies, 5 open or runningNext primary completion: Jul 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticalsits history only251 open or runningphase 4since Nov 2, 2012May 13, 2002none ahead
Bayerits history only230 open or runningphase 4since Apr 10, 2014Mar 12, 2008none ahead
Sanofi200 open or runningphase 3since May 16, 2006Jan 30, 2006none ahead
Novartisits history only40 open or runningphase 4since Jul 22, 2016Jul 22, 2016none ahead
Amgenits history only31 open or runningphase 3since Feb 13, 2020Feb 13, 2020Jul 31, 2027phase 3 · NCT07614776
Sam Chun Dang Pharm.its history only20 open or runningphase 3since Jul 17, 2020Jul 17, 2020none ahead
AbbVieits history only11 open or runningphase 2since Mar 16, 2022Mar 16, 2022Jun 2031phase 2 · NCT05296447
AO GENERIUMits history only11 open or runningphase 3since Sep 18, 2026Sep 18, 2026May 2028phase 3 · NCT07844148
bioeq-gmbhits history only10 open or runningphase 3since Aug 11, 2020Aug 11, 2020none ahead
cinnagenits history only10 open or runningphase 3since Sep 18, 2022Sep 18, 2022none ahead

Also a collaborator on its studies: REGENXBIO and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Jan 30, 2006.

  1. Sep 19, 2007Phase 3 study in CarcinomaNCT00532155 · 913 enrolled · United States, Argentina, Australia and more
  2. Oct 16, 2007Phase 1 study in NeoplasmsNCT00545246 · 12 enrolled · Japan
  3. Nov 20, 2007Phase 3 study in Colorectal NeoplasmsNCT00561470 · 1,226 enrolled · United States, Argentina, Australia and more
  4. Dec 14, 2007Phase 3 study in Pancreatic NeoplasmsNCT00574275 · 546 enrolled · United States, Argentina, Austria and more
  5. Mar 21, 2008Phase 1 study in Lymphoma, Non-HodgkinNCT00644124 · 25 enrolled · France
  6. Feb 24, 2009Phase 2 study in Colorectal NeoplasmsNCT00851084 · 268 enrolled · Australia, Germany, Italy and more
  7. Apr 3, 2009Phase 1 study in NeoplasmsNCT00876044 · 88 enrolled · United States, Belgium, Denmark and more
  8. Jun 15, 2009Phase 1 study in Colorectal NeoplasmsNCT00921661 · 16 enrolled · Japan
  9. Jun 21, 2010Phase 1 study in NeoplasmsNCT01148615 · 20 enrolled · China
  10. Apr 3, 2012Phase 3 study in Colorectal Cancer MetastaticNCT01571284 · 781 enrolled · United States, Belgium, Brazil and more
  11. Jul 13, 2012Phase 3 study in Colorectal Cancer MetastaticNCT01670721 · 175 enrolled · France
  12. Aug 7, 2012Phase 3 study in Colorectal Cancer MetastaticNCT01661270 · 332 enrolled · China, Hong Kong, Japan and more
  13. Jun 18, 2013Phase 2 study in Colorectal Cancer MetastaticNCT01882868 · 62 enrolled · Japan
  14. Sep 13, 2013Phase 2 study in Colorectal Cancer MetastaticNCT01955629 · 4 enrolled · Italy
  15. Jul 21, 2022Named afliberceptINNProposed as its International Nonproprietary Name in WHO's List 127

TargetBeta

PGF →VEGFA →read by rule
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule

Studies

All 20 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01955629Colorectal Cancer Metastatic · Italy2TerminatedMar 20154
NCT01882868Colorectal Cancer Metastatic · Japan2CompletedAug 201562
NCT01661270Colorectal Cancer Metastatic · China, Hong Kong, Japan and more3CompletedOct 2014332
NCT01670721Colorectal Cancer Metastatic · France3CompletedJun 2015175
NCT01571284Colorectal Cancer Metastatic · United States, Belgium, Brazil and more3CompletedJan 31, 2017781
NCT01148615Neoplasms · China1CompletedSep 201120
NCT00921661Colorectal Neoplasms · Japan1CompletedJun 201216
NCT00876044Neoplasms · United States, Belgium, Denmark and more1CompletedFeb 201088
NCT00851084Colorectal Neoplasms · Australia, Germany, Italy and more2CompletedApr 2011268
NCT00644124Lymphoma, Non-Hodgkin · France1CompletedOct 201125
NCT00574275Pancreatic Neoplasms · United States, Argentina, Austria and more3TerminatedOct 2009546
NCT00561470Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedFeb 20111,226
NCT00545246Neoplasms · Japan1CompletedJul 201212
NCT00532155Carcinoma · United States, Argentina, Australia and more3CompletedJan 2011913
NCT00519285Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedApr 20121,224
NCT00479076Neoplasms · Japan1CompletedJan 201122
NCT00396591Ovarian Neoplasms · United States, Italy, Sweden2CompletedNov 200816
NCT00327444Ovarian Neoplasms · United States, Austria, Belgium and more3CompletedOct 200958
NCT00327171Neoplasms · United States, Australia, Canada and more2CompletedApr 2008218
NCT00284141Lung Diseases · United States, Canada, France2CompletedJul 200898

How it is read

Names in the registry

  • “Aflibercept”, 9 entries
  • “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept”, 7 entries
  • “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries

Codes read as this program: BAY865321, SCD411.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.